ArticleJournal of medicinal chemistry2022

Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Andrea Luraghi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.